The Emerging Role of AI in Supply Chain Management
By

By
An expert panel at a DCAT Week education program will examine how AI may change how bio/pharma companies and their suppliers will do business. Will your next supply deal be negotiated by AI? Can AI protect your company from costly supply-chain disruptions?

Euroapi Announces Restructuring Plan
By

By
Euroapi, the spin-out CDMO business of Sanofi, now a stand-alone entity, announced a restructuring plan this week and appointed a new CEO as a means to improve company performance. What challenges and opportunities does the CDMO face? DCAT Value Chain Insights takes an inside look.

How Will the Pharma Industry Perform in 2024 & the Near Term?
By

By
With 2024 well underway, the crucial question for both bio/pharma companies and their suppliers is: how will the industry perform in 2024 and the near term? Get the answer to that all-important question at the Pharma Industry Outlook education program at DCAT Week.

Congress Launches Probe into Certain Drug Shortages; Seeking Company Input
By

By
Certain members of the House Committee on Oversight and Accountability have initiated an investigation into three long-standing, separate drug shortages, respectively seeking input from Teva, Sandoz, and Pfizer on their responses to their shortages and related manufacturing issues.

What’s Trending: Parenteral Drug Development & Manufacturing
By

By
What are some key trends and issues arising in parenteral drug development and manufacturing? From more complex molecules and modalities and sterile drug-product capacity market shifts, DCAT Value Chain Insights takes an inside look.

In the Spotlight: FDA’s Inspections of Foreign Drug Mfg Facilities
By

By
The FDA’s inspection process for foreign drug-manufacturing facilities came under scrutiny once again with Congress holding a hearing questioning the frequency and quality of FDA’s foreign drug inspections. What may be next?

Manufacturing Fallout of Novo’s $16.5-Billion Acquisition of Catalent
By

By
The CDMO/CMO sector had a major shakeup with Novo Holdings, the parent company of Novo Nordisk, announcing it had agreed to acquire Catalent for $16.5 billion. What is the strategy behind the deal and the implications on a manufacturing basis?

The CDMO/CMO and Suppliers’ Report: Small-Molecule APIs
By

By
Which CDMOs/CDMO are expanding manufacturing capacity for intermediates and small-molecule active pharmaceutical ingredients (APIs)? DCAT Value Chain Insights gives a roundup of recently announced, in-progress, and completed expansions.

Up or Down: The Key Trends in New Drug Approvals
By

By
How did the industry fare with new drug approvals in 2023? What do the numbers show? Are approvals in pace with prior years, and what is the mix between small molecules and biologics? Which companies and products made the mark?

US Gov’t Takes Next Step in Drug Pricing Reform
By

By
The US government is sending initial offers to participating bio/pharmaceutical companies of the first 10 Rx drugs selected for negotiation in the first cycle of the Medicare Drug Price Negotiation Program. Which companies & products are affected?